GlassScriptPhysician profile
Erik P Thyssen
NPI 1750495099
$7,739.97
in general payments reported to CMS, 2019-2025
32 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $636 · 2021: $607 · 2022: $722 · 2023: $1,117 · 2024: $1,973 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,294 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,293.77 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,962.24 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,421.12 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $546.56 | 2021-2025 | |
| Pfizer INC. | $512.69 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $453.07 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $226.16 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $178.20 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $170.00 | 2019-2024 | Linzess |
| Lilly USA, LLC | $139.31 | 2024-2025 | Omvoh |
| Ucb, INC. | $135.62 | 2019-2020 | |
| Dova Pharmaceuticals | $132.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.19 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $126.52 | 2023-2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $99.72 | 2021 | |
| Romark Laboratories, Lc | $89.64 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.56 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $48.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $41.91 | 2019 | |
| Redhill Biopharma INC. | $39.57 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Micro-Tech Endoscopy USA, INC. | $38.90 | 2025 | Cold Snares, Buttons |
| Braintree Laboratories, INC. | $35.56 | 2019-2021 | |
| Organon LLC | $26.62 | 2024 | |
| Amgen INC. | $18.73 | 2022 | |
| Ardelyx, INC. | $17.95 | 2024 | Ibsrela |
| Sandoz INC. | $16.20 | 2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $15.61 | 2024 | |
| Qol Medical, LLC | $15.15 | 2025 | Sucraid |
| Daiichi Sankyo INC. | $14.49 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.60 | 2020 | |
| Mauna Kea Technologies, INC. | $11.77 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.39 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22,836.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Thyssen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.